Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data

 April 8, 2026

BioSpace

Another bidder, which remains unidentified, dropped out of the bidding process.

M&A / DealsHematologyRead full story

Post navigation

List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun) →
← Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com